tranexamic acid has been researched along with Thrombocytopenia in 26 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Thrombocytopenia: A subnormal level of BLOOD PLATELETS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders." | 9.30 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019) |
| "A controlled, randomized, double-blind study was performed to assess the effect of the oral antifibrinolytic agent tranexamic acid in patients with amegakaryocytic thrombocytopenia as regards their need for platelet transfusions and the number of bleeding episodes experienced." | 9.07 | Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. ( Alling, D; Fricke, W; Griffith, P; Kimball, J; Klein, H, 1991) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 8.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders." | 8.89 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013) |
| "The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders." | 8.31 | Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023) |
| "This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders." | 5.30 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019) |
| "Tranexamic acid was extremely well tolerated in this newborn." | 5.28 | Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. ( Bernstein, M; Hanna, BD, 1989) |
| "A controlled, randomized, double-blind study was performed to assess the effect of the oral antifibrinolytic agent tranexamic acid in patients with amegakaryocytic thrombocytopenia as regards their need for platelet transfusions and the number of bleeding episodes experienced." | 5.07 | Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. ( Alling, D; Fricke, W; Griffith, P; Kimball, J; Klein, H, 1991) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 4.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders." | 4.89 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013) |
| "The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders." | 4.31 | Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023) |
| "Tranexamic acid has been advocated for patients with severe bleeding tendency due to thrombocytopenia not responding to platelet transfusions." | 3.69 | Microscopic haematuria as a relative contraindication for tranexamic acid. ( Schultz, M; van der Lelie, H, 1995) |
| "The most robust data for the treatment of menorrhagia are for tranexamic acid." | 2.47 | Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. ( Bates, JS; Buie, LW; Woodis, CB, 2011) |
| "Tranexamic acid was extremely well tolerated in this newborn." | 1.28 | Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants. ( Bernstein, M; Hanna, BD, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (15.38) | 18.7374 |
| 1990's | 7 (26.92) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ilich, A | 1 |
| Gernsheimer, TB | 1 |
| Triulzi, DJ | 1 |
| Herren, H | 1 |
| Brown, SP | 1 |
| Holle, LA | 1 |
| Lucas, AT | 1 |
| de Laat, B | 1 |
| El Kassar, N | 1 |
| Wolberg, AS | 1 |
| May, S | 1 |
| Key, NS | 1 |
| Estcourt, LJ | 4 |
| McQuilten, Z | 1 |
| Powter, G | 1 |
| Dyer, C | 1 |
| Curnow, E | 1 |
| Wood, EM | 1 |
| Stanworth, SJ | 3 |
| Wardrop, D | 1 |
| Brunskill, SJ | 2 |
| Doree, C | 3 |
| Trivella, M | 2 |
| Stanworth, S | 1 |
| Murphy, MF | 2 |
| Schlitter, MC | 1 |
| Rühl, H | 1 |
| Thiesler, T | 1 |
| Penner, AH | 1 |
| Berens, C | 1 |
| Wolf, D | 1 |
| Mayer, K | 1 |
| Revollo, JY | 1 |
| Cuffy, MC | 1 |
| Witte, DP | 1 |
| Paterno, F | 1 |
| Alloway, RR | 1 |
| Woodle, ES | 1 |
| Desborough, M | 2 |
| Hopewell, S | 2 |
| Hadjinicolaou, AV | 1 |
| Chaimani, A | 1 |
| Vyas, P | 1 |
| Tay, J | 1 |
| Allan, D | 1 |
| Beattie, S | 1 |
| Bredeson, C | 1 |
| Fergusson, D | 1 |
| Maze, D | 1 |
| Sabloff, M | 1 |
| Thavorn, K | 1 |
| Tinmouth, A | 1 |
| Yadav, SP | 1 |
| Sachdeva, A | 1 |
| Bhat, S | 1 |
| Katewa, S | 1 |
| Kerros, H | 1 |
| Roule, V | 1 |
| Ivascau, C | 1 |
| Labombarda, F | 1 |
| Bates, JS | 1 |
| Buie, LW | 1 |
| Woodis, CB | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Coppola, A | 1 |
| Simone, CD | 1 |
| Palmieri, NM | 1 |
| Coppola, D | 1 |
| Lanza, F | 1 |
| Ruosi, C | 1 |
| Amoriello, A | 1 |
| Di Minno, G | 1 |
| Mori, T | 1 |
| Aisa, Y | 1 |
| Shimizu, T | 1 |
| Yamazaki, R | 1 |
| Mihara, A | 1 |
| Yajima, T | 1 |
| Hibi, T | 1 |
| Ikeda, Y | 1 |
| Okamoto, S | 1 |
| Astedt, B | 1 |
| Henriksson, P | 1 |
| Nilsson, IM | 1 |
| Svanberg, L | 1 |
| Schultz, M | 1 |
| van der Lelie, H | 1 |
| Fernández Lucas, M | 1 |
| Liaño, F | 1 |
| Navarro, JF | 1 |
| Sastre, JL | 1 |
| Quereda, C | 1 |
| Ortuño, J | 1 |
| O'Brien, JG | 2 |
| Battistini, B | 2 |
| Farmer, P | 2 |
| Johnson, RJ | 2 |
| Zaharia, F | 2 |
| Plante, GE | 1 |
| Sirois, P | 2 |
| Katsaros, D | 1 |
| Grundfest-Broniatowski, S | 1 |
| Gortzak, RA | 1 |
| Huijgens, PC | 1 |
| Lindquist, O | 1 |
| Bagge, L | 1 |
| Saldeen, T | 1 |
| Fricke, W | 1 |
| Alling, D | 1 |
| Kimball, J | 1 |
| Griffith, P | 1 |
| Klein, H | 1 |
| Hanna, BD | 1 |
| Bernstein, M | 1 |
| Bell, AJ | 1 |
| Chisholm, M | 1 |
| Hickton, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia[NCT03136445] | Phase 3 | 616 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Platelet Transfusion Requirements in Hematopoietic Transplantation(PATH Pilot)[NCT02650791] | Phase 3 | 100 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for tranexamic acid and Thrombocytopenia
| Article | Year |
|---|---|
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2013 |
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2016 |
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Topics: Benzoates; Bone Marrow Diseases; Chronic Disease; Deamino Arginine Vasopressin; Hemorrhage; Hemostat | 2016 |
Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy.
Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Meno | 2011 |
Management of coagulation: an Australian perspective.
Topics: Australia; Blood Coagulation Disorders; Factor VIIa; Hemorrhage; Humans; Perioperative Care; Platele | 2012 |
3 trials available for tranexamic acid and Thrombocytopenia
| Article | Year |
|---|---|
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Australia; Double-Blind | 2019 |
Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Platelets; Female; Hematopoietic Stem Cell Transpl | 2016 |
Lack of efficacy of tranexamic acid in thrombocytopenic bleeding.
Topics: Anemia, Aplastic; Blood Transfusion; Hemorrhage; Humans; Myelodysplastic Syndromes; Platelet Transfu | 1991 |
18 other studies available for tranexamic acid and Thrombocytopenia
| Article | Year |
|---|---|
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans | 2023 |
Ilich A, Gernsheimer TB, Triulzi DJ, et al. Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. Blood Adv. 2023;7(6):900-908.
Topics: Blood Coagulation Disorders; Humans; Thrombocytopenia; Tranexamic Acid | 2023 |
Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma.
Topics: Blood Component Transfusion; Chest Pain; Combined Modality Therapy; Disseminated Intravascular Coagu | 2014 |
Case Report: Hemolytic Anemia Following Deceased Donor Renal Transplantation Associated With Tranexamic Acid Administration for Disseminated Intravascular Coagulation.
Topics: Aged; Anemia, Hemolytic; Antifibrinolytic Agents; Diabetes Mellitus, Type 2; Disseminated Intravascu | 2015 |
Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion.
Topics: beta-Thalassemia; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Delayed Graft F | 2010 |
Management of May-Hegglin anomaly referred for coronary artery bypass.
Topics: Adult; Anesthetics; Blood Platelets; Cell Size; Coronary Artery Bypass; Diabetes Complications; Diab | 2011 |
Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome.
Topics: Adolescent; Blood Loss, Surgical; Blood Platelet Disorders; Drug Administration Schedule; Factor VII | 2007 |
Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Antifibrinolytic Agents; Bilirubin; Child; Female; Hematopoietic Stem Cell Transplantation; Hepatic | 2007 |
Regression of hemangioma--thrombocytopenia syndrome.
Topics: Adolescent; Female; Hemangioma; Humans; Syndrome; Thrombocytopenia; Tranexamic Acid; Uterine Neoplas | 1982 |
Microscopic haematuria as a relative contraindication for tranexamic acid.
Topics: Adult; Contraindications; Female; Hematuria; Hemorrhagic Disorders; Humans; Male; Middle Aged; Throm | 1995 |
Acute renal failure secondary to antifibrinolytic therapy.
Topics: Acute Kidney Injury; Aged; Humans; Male; Myelodysplastic Syndromes; Thrombocytopenia; Tranexamic Aci | 1995 |
Aprotinin, an antifibrinolytic drug, attenuates bradykinin-induced permeability in conscious rats via platelets and neutrophils.
Topics: Animals; Antifibrinolytic Agents; Aprotinin; Blood Platelets; Bradykinin; Capillary Permeability; Ce | 1997 |
Effects of tranexamic acid and aprotinin on PAF-induced vascular permeability in normal, thrombocytopenic or neutropenic rats.
Topics: Animals; Antifibrinolytic Agents; Aprotinin; Bronchi; Capillary Permeability; Male; Neutropenia; Pla | 1997 |
Successful management of visceral Klippel-Trenaunay-Weber syndrome with the antifibrinolytic agent tranexamic acid (cyclocapron): a case report.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Tests; Colon, Sigmoid; Disseminated Intravascular | 1998 |
[A patient with thrombocytopenia: what do I do?].
Topics: Adult; Antifibrinolytic Agents; Humans; Male; Methylprednisolone; Oral Hemorrhage; Postoperative Car | 1999 |
Induction of endogenous fibrinolysis inhibition in the dog. Effect of intravascular coagulation and release of free fatty acids.
Topics: Animals; Batroxobin; Blood Platelets; Dogs; Endotoxins; Fatty Acids, Nonesterified; Female; Fibrinol | 1976 |
Tranexamic acid in the treatment of Kasabach-Merritt syndrome in infants.
Topics: Cyclohexanecarboxylic Acids; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fema | 1989 |
Reversal of coagulopathy in Kasabach-Merritt syndrome with tranexamic acid.
Topics: Afibrinogenemia; Blood Coagulation Disorders; Buttocks; Combined Modality Therapy; Cyclohexanecarbox | 1986 |